Skip to content
DraconiticResearch
Search Sources API
179,152 studies31 sourcesUpdated 1 h ago
Peer-reviewedCC BY-NCHaematologica

Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study

  • Meunier Mathieu
  • Sylvain Thépot
  • Stanislas Nimubona
  • Mélanie Veloso
  • Thibaud Lefebvre
  • Zoubida Karim
  • Martine Ropert-Bouchet
  • Frédéric Garban
  • Shanti Ame
  • Claire Reynes
  • Celia Salanoubat
  • Vincent Parinet
13 more authors
  • Kamel Laribi
  • Pirayeh Eftekhari
  • Jacques Delaunay
  • Geoffroy Venton
  • Clemence Santana
  • Stéphane Cheze
  • Sophie Dimicoli-Salazar
  • Andrea Toma
  • Mathieu Molimard
  • Pierre Fenaux
  • Valérie Rolland-Neyret
  • Sandra David-Tchouda
  • Sophie Park
Open at sourcePDFDOICite

Related

  1. APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.
    Raimbault A, Pierre-Eugene C, Rouquette A +10
    OncotargetPeer-reviewedCC BY11 citedGeneral biologyGeneral medicineHAL
  2. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Valérie Bardet, Wagner-Ballon O, Guy J +12
    HaematologicaPeer-reviewedLicence not statedFull text43 citedGeneral biologyGeneral medicineHAL
  3. The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.
    Raimbault A, Itzykson R, Willems L +9
    Cytometry. Part B, Clinical cytometryPeer-reviewedLicence not statedFull text16 citedGeneral biologyGeneral medicineHAL
  4. The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes
    Dominic Culligan, Adele Taylor, Alexandra Smith +17
    eJHaemPeer-reviewedCC BYGeneral biologyHAL
  5. Transcriptional contingency in the early hematopoiesis of inherited bone marrow failure syndromes
    A. A. De la Cruz, P. Siliceo, U. Juarez Figueroa +3
    bioRxivPreprintCC BYFull textGenetics & genomicsbioRxiv

Cite

BibTeXRIS
BibTeX
@article{mathieu2026lowdose,
  title = {{Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study}},
  author = {Meunier Mathieu and Sylvain Thépot and Stanislas Nimubona and Mélanie Veloso and Thibaud Lefebvre and Zoubida Karim and Martine Ropert-Bouchet and Frédéric Garban and Shanti Ame and Claire Reynes and Celia Salanoubat and Vincent Parinet and Kamel Laribi and Pirayeh Eftekhari and Jacques Delaunay and Geoffroy Venton and Clemence Santana and Stéphane Cheze and Sophie Dimicoli-Salazar and Andrea Toma and Mathieu Molimard and Pierre Fenaux and Valérie Rolland-Neyret and Sandra David-Tchouda and Sophie Park},
  journal = {Haematologica},
  year = {2026},
  month = oct,
  doi = {10.3324/haematol.2026.301420},
  url = {https://hal.science/hal-05786255v1},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study
AU  - Meunier Mathieu
AU  - Sylvain Thépot
AU  - Stanislas Nimubona
AU  - Mélanie Veloso
AU  - Thibaud Lefebvre
AU  - Zoubida Karim
AU  - Martine Ropert-Bouchet
AU  - Frédéric Garban
AU  - Shanti Ame
AU  - Claire Reynes
AU  - Celia Salanoubat
AU  - Vincent Parinet
AU  - Kamel Laribi
AU  - Pirayeh Eftekhari
AU  - Jacques Delaunay
AU  - Geoffroy Venton
AU  - Clemence Santana
AU  - Stéphane Cheze
AU  - Sophie Dimicoli-Salazar
AU  - Andrea Toma
AU  - Mathieu Molimard
AU  - Pierre Fenaux
AU  - Valérie Rolland-Neyret
AU  - Sandra David-Tchouda
AU  - Sophie Park
PY  - 2026
DA  - 2026/10/08
JO  - Haematologica
DO  - 10.3324/haematol.2026.301420
UR  - https://hal.science/hal-05786255v1
SN  - 0390-6078
SN  - 1592-8721
ER  -